Cytoprotective and supportive care agents:

Indications for: XERMELO

In combination with somatostatin analog (SSA) therapy, to treat carcinoid syndrome diarrhea in adults inadequately controlled by SSA therapy.

Adult Dosage:

Take with food. 250mg 3 times daily.

Children Dosage:

Not established.

XERMELO Warnings/Precautions:

Monitor for constipation and/or severe, persistent, or worsening abdominal pain; discontinue if develops. Moderate and severe hepatic impairment: not recommended. ESRD requiring dialysis: not studied. Pregnancy. Nursing mothers: monitor infant for constipation.

XERMELO Classification:

Tryptophan hydroxylase inhibitor.

XERMELO Interactions:

May antagonize CYP3A4 (eg, midazolam) or CYP2B6 substrates (eg, bupropion, efavirenz); monitor and consider increasing dose of interacting drug if necessary. Antagonized by short-acting octreotide; if concomitant use is necessary, give dose ≥30mins after Xermelo.

Adverse Reactions:

Nausea, headache, increased GGT, depression, flatulence, decreased appetite, peripheral edema, pyrexia.

Generic Drug Availability:


How Supplied:

Tabs—84 (monthly case)